<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:georss="http://www.georss.org/georss" xmlns:geo="http://www.w3.org/2003/01/geo/wgs84_pos#" xmlns:media="http://search.yahoo.com/mrss/"
	>

<channel>
	<title>CardioBrief</title>
	<atom:link href="http://cardiobrief.org/feed/" rel="self" type="application/rss+xml" />
	<link>http://cardiobrief.org</link>
	<description>One-stop source for cardiology news and links</description>
	<lastBuildDate>Fri, 17 May 2013 19:14:07 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.com/</generator>
<cloud domain='cardiobrief.org' port='80' path='/?rsscloud=notify' registerProcedure='' protocol='http-post' />
<image>
		<url>http://1.gravatar.com/blavatar/5706effc1b2c62d7b9c46c6c74eb5d86?s=96&#038;d=http%3A%2F%2Fs2.wp.com%2Fi%2Fbuttonw-com.png</url>
		<title>CardioBrief</title>
		<link>http://cardiobrief.org</link>
	</image>
	<atom:link rel="search" type="application/opensearchdescription+xml" href="http://cardiobrief.org/osd.xml" title="CardioBrief" />
	<atom:link rel='hub' href='http://cardiobrief.org/?pushpress=hub'/>
		<item>
		<title>Instagram for Heart Attacks: iPhone App Speeds ECG Transmission To Hospital</title>
		<link>http://cardiobrief.org/2013/05/17/instagram-for-heart-attacks-iphone-app-speeds-ecg-transmission-to-hospital/</link>
		<comments>http://cardiobrief.org/2013/05/17/instagram-for-heart-attacks-iphone-app-speeds-ecg-transmission-to-hospital/#comments</comments>
		<pubDate>Fri, 17 May 2013 19:09:10 +0000</pubDate>
		<dc:creator>Larry Husten</dc:creator>
				<category><![CDATA[MI/ACS]]></category>
		<category><![CDATA[People, Places & Events]]></category>
		<category><![CDATA[ECG]]></category>
		<category><![CDATA[Electrocardiography]]></category>
		<category><![CDATA[EMT]]></category>
		<category><![CDATA[iPhone]]></category>
		<category><![CDATA[myocardial infarction]]></category>
		<category><![CDATA[STEMI]]></category>

		<guid isPermaLink="false">http://cardiobrief.org/?p=14209</guid>
		<description><![CDATA[In the crucial early stages of a possible heart attack, EMTs on the scene now rely on slow and unreliable proprietary technology to transmit vital ECG data to physicians at a hospital for evaluation. But a new iPhone app using standard cell phone networks may help speed the process and, ultimately,  cut delays in treatment for heart attack patients. In a presentation earlier today at the American Heart Association&#8217;s Quality of Care and Outcomes Research Scientific Sessions 2013 meeting in Baltimore, faculty and students at the University of Virginia designed an iPhone app to overcome <a class="entry-excerpt-link" href="http://cardiobrief.org/2013/05/17/instagram-for-heart-attacks-iphone-app-speeds-ecg-transmission-to-hospital/">More&#8230;</a><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=cardiobrief.org&#038;blog=6145391&#038;post=14209&#038;subd=cardiobrief&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://cardiobrief.org/2013/05/17/instagram-for-heart-attacks-iphone-app-speeds-ecg-transmission-to-hospital/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://2.gravatar.com/avatar/5942cc097b5e0e6b0bc9d26e5c4fb3a1?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">Larry</media:title>
		</media:content>

		<media:content url="http://b-i.forbesimg.com/larryhusten/files/2013/05/iPhone-ECG-app.jpg" medium="image" />
	</item>
		<item>
		<title>Salt Report From IOM Sparks Much Heat, Only A Little Light</title>
		<link>http://cardiobrief.org/2013/05/16/salt-report-from-iom-sparks-much-heat-only-a-little-light/</link>
		<comments>http://cardiobrief.org/2013/05/16/salt-report-from-iom-sparks-much-heat-only-a-little-light/#comments</comments>
		<pubDate>Thu, 16 May 2013 15:42:28 +0000</pubDate>
		<dc:creator>Larry Husten</dc:creator>
				<category><![CDATA[People, Places & Events]]></category>
		<category><![CDATA[Policy & Ethics]]></category>
		<category><![CDATA[Prevention, Epidemiology & Outcomes]]></category>
		<category><![CDATA[american heart association]]></category>
		<category><![CDATA[Gina Kolata]]></category>
		<category><![CDATA[Institute of Medicine]]></category>
		<category><![CDATA[New York Times]]></category>
		<category><![CDATA[salt]]></category>

		<guid isPermaLink="false">http://cardiobrief.org/?p=14207</guid>
		<description><![CDATA[An Institute of Medicine report on salt earlier this week sparked a lot of controversy. The report concludes that there&#8217;s no evidence to support current efforts to lower salt consumption to less than 2,300 mg/day. Unfortunately, the press coverage offered little insight into the science behind the issue. On the Knight Science Journalism Tracker blog, Faye Flam deftly uncovers the almost universal shallow coverage in the media. The one exception, the one story worth reading that &#8220;dug into the science,&#8221; according to Flam, is Gina Kolata&#8217;s story in the New York Times: &#8230; Click here <a class="entry-excerpt-link" href="http://cardiobrief.org/2013/05/16/salt-report-from-iom-sparks-much-heat-only-a-little-light/">More&#8230;</a><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=cardiobrief.org&#038;blog=6145391&#038;post=14207&#038;subd=cardiobrief&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://cardiobrief.org/2013/05/16/salt-report-from-iom-sparks-much-heat-only-a-little-light/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://2.gravatar.com/avatar/5942cc097b5e0e6b0bc9d26e5c4fb3a1?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">Larry</media:title>
		</media:content>

		<media:content url="http://b-i.forbesimg.com/larryhusten/files/2013/05/300px-Salt_Crystals9.jpg" medium="image">
			<media:title type="html">English: A close up of salt crystals.</media:title>
		</media:content>
	</item>
		<item>
		<title>Study Questions Role Of Dual-Chamber ICDs For Primary Prevention</title>
		<link>http://cardiobrief.org/2013/05/14/study-questions-role-of-dual-chamber-icds-for-primary-prevention/</link>
		<comments>http://cardiobrief.org/2013/05/14/study-questions-role-of-dual-chamber-icds-for-primary-prevention/#comments</comments>
		<pubDate>Tue, 14 May 2013 20:00:14 +0000</pubDate>
		<dc:creator>Larry Husten</dc:creator>
				<category><![CDATA[Heart Rhythms]]></category>
		<category><![CDATA[Complications]]></category>
		<category><![CDATA[heart failure]]></category>
		<category><![CDATA[ICDs]]></category>
		<category><![CDATA[implantable cardioverter defibrillator]]></category>
		<category><![CDATA[JAMA]]></category>
		<category><![CDATA[Preventive medicine]]></category>

		<guid isPermaLink="false">http://cardiobrief.org/?p=14177</guid>
		<description><![CDATA[Dual-chamber ICDs are implanted in a majority of primary prevention patients without a pacing indication who receive an ICD. Although there are a number of theoretical advantages with dual-chamber devices, these devices are more likely to cause complications. Although CMS requires providers to justify the medical necessity of dual-chamber devices, current guidelines from the AHA/ACC and HRS do not specify a single-chamber device. In a new study published in JAMA, Pamela Peterson and colleagues analyzed data from 32,000 primary prevention patients without a pacing indication who were enrolled in the National Cardiovascular Data Registry (NCDR). 38% received <a class="entry-excerpt-link" href="http://cardiobrief.org/2013/05/14/study-questions-role-of-dual-chamber-icds-for-primary-prevention/">More&#8230;</a><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=cardiobrief.org&#038;blog=6145391&#038;post=14177&#038;subd=cardiobrief&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://cardiobrief.org/2013/05/14/study-questions-role-of-dual-chamber-icds-for-primary-prevention/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://2.gravatar.com/avatar/5942cc097b5e0e6b0bc9d26e5c4fb3a1?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">Larry</media:title>
		</media:content>

		<media:content url="http://b-i.forbesimg.com/larryhusten/files/2013/05/NCDR-logo.jpg" medium="image" />
	</item>
		<item>
		<title>Novel Leadless Pacemaker Makes Debut At HRS 2013</title>
		<link>http://cardiobrief.org/2013/05/13/novel-leadless-pacemaker-makes-debut-at-hrs-2013/</link>
		<comments>http://cardiobrief.org/2013/05/13/novel-leadless-pacemaker-makes-debut-at-hrs-2013/#comments</comments>
		<pubDate>Mon, 13 May 2013 17:30:17 +0000</pubDate>
		<dc:creator>Larry Husten</dc:creator>
				<category><![CDATA[Heart Rhythms]]></category>
		<category><![CDATA[Interventional Cardiology & Surgery]]></category>
		<category><![CDATA[Heart Rhythm Society]]></category>
		<category><![CDATA[leadless pacemaker]]></category>
		<category><![CDATA[Nanostim]]></category>
		<category><![CDATA[st jude medical]]></category>

		<guid isPermaLink="false">http://cardiobrief.org/?p=14173</guid>
		<description><![CDATA[First results in human patients of a novel leadless pacemaker were presented last week at the HRS meeting in Denver by Vivek Reddy.  Pacemaker leads are the most common source of complications associated with pacemakers today. The self-contained device is delivered via catheter to the right ventricle, to which it is attached with a fixation mechanism.  The device is manufactured by Nanostim, Inc, a small company which is being acquired by St. Jude Medical. &#8230; Click here to read the full story on Forbes. &#160; &#160; &#160;<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=cardiobrief.org&#038;blog=6145391&#038;post=14173&#038;subd=cardiobrief&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://cardiobrief.org/2013/05/13/novel-leadless-pacemaker-makes-debut-at-hrs-2013/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://2.gravatar.com/avatar/5942cc097b5e0e6b0bc9d26e5c4fb3a1?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">Larry</media:title>
		</media:content>

		<media:content url="http://www.cardioexchange.org/wp-content/uploads/2013/05/Leadless.jpg" medium="image">
			<media:title type="html">Leadless</media:title>
		</media:content>
	</item>
		<item>
		<title>Our Limitless Capacity For Self-Deception</title>
		<link>http://cardiobrief.org/2013/05/12/our-limitless-capacity-for-self-deception/</link>
		<comments>http://cardiobrief.org/2013/05/12/our-limitless-capacity-for-self-deception/#comments</comments>
		<pubDate>Sun, 12 May 2013 18:50:54 +0000</pubDate>
		<dc:creator>Larry Husten</dc:creator>
				<category><![CDATA[Policy & Ethics]]></category>
		<category><![CDATA[advertising]]></category>
		<category><![CDATA[conflict of interest]]></category>
		<category><![CDATA[ethics]]></category>
		<category><![CDATA[medical ethics]]></category>

		<guid isPermaLink="false">http://cardiobrief.org/?p=14169</guid>
		<description><![CDATA[I want to share with my readers a recent post and accompanying comment published on CardioExchange. The original post is by Eric Lindley, a cardiology fellow at the University of Utah: Journal X: Not so Subtle Marketing Messages I was the rare resident who thought that conflict of interest issues in medicine were a bit overblown. I did not find (or ignored) the evidence that pharma played a role in prescribing habits very persuasive, at least not when it came to my personal prescribing habits. I was not alone among the house staff, however, in appreciating an <a class="entry-excerpt-link" href="http://cardiobrief.org/2013/05/12/our-limitless-capacity-for-self-deception/">More&#8230;</a><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=cardiobrief.org&#038;blog=6145391&#038;post=14169&#038;subd=cardiobrief&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://cardiobrief.org/2013/05/12/our-limitless-capacity-for-self-deception/feed/</wfw:commentRss>
		<slash:comments>10</slash:comments>
	
		<media:content url="http://2.gravatar.com/avatar/5942cc097b5e0e6b0bc9d26e5c4fb3a1?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">Larry</media:title>
		</media:content>

		<media:content url="http://b-i.forbesimg.com/larryhusten/files/2013/05/Xarelto-X.jpg" medium="image" />
	</item>
		<item>
		<title>Suspicions Raised About Another Japanese Cardiovascular Researcher</title>
		<link>http://cardiobrief.org/2013/05/10/suspicions-raised-about-another-japanese-cardiovascular-researcher/</link>
		<comments>http://cardiobrief.org/2013/05/10/suspicions-raised-about-another-japanese-cardiovascular-researcher/#comments</comments>
		<pubDate>Fri, 10 May 2013 21:11:39 +0000</pubDate>
		<dc:creator>Larry Husten</dc:creator>
				<category><![CDATA[People, Places & Events]]></category>
		<category><![CDATA[Policy & Ethics]]></category>
		<category><![CDATA[scientific misconduct]]></category>

		<guid isPermaLink="false">http://cardiobrief.org/?p=14167</guid>
		<description><![CDATA[Significant questions about research misconduct have been raised about a prominent Japanese cardiovascular researcher, Issei Komuro. Last year a Nature paper on which Komuro served as a co-author was corrected because &#8220;several images were mistakenly switched or duplicated during preparation of the artwork.&#8221; The Nature correction states that the &#8220;corrections do not alter any of the conclusions&#8221; of the paper. Now, however, a Japanese blog, entitled Issei Komuro &#8211; image manipulation -, raises questions about 13 additional papers. The papers were all published in well-known journals, including a second Nature paper, Nature Medicine, and 4 <a class="entry-excerpt-link" href="http://cardiobrief.org/2013/05/10/suspicions-raised-about-another-japanese-cardiovascular-researcher/">More&#8230;</a><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=cardiobrief.org&#038;blog=6145391&#038;post=14167&#038;subd=cardiobrief&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://cardiobrief.org/2013/05/10/suspicions-raised-about-another-japanese-cardiovascular-researcher/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://2.gravatar.com/avatar/5942cc097b5e0e6b0bc9d26e5c4fb3a1?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">Larry</media:title>
		</media:content>

		<media:content url="http://b-i.forbesimg.com/larryhusten/files/2013/05/Komuru.jpg" medium="image" />
	</item>
		<item>
		<title>Encouraging 4 Year Results For Watchman Device In AF Patients</title>
		<link>http://cardiobrief.org/2013/05/10/encouraging-4-year-results-for-watchman-device-in-af-patients/</link>
		<comments>http://cardiobrief.org/2013/05/10/encouraging-4-year-results-for-watchman-device-in-af-patients/#comments</comments>
		<pubDate>Fri, 10 May 2013 17:10:56 +0000</pubDate>
		<dc:creator>Larry Husten</dc:creator>
				<category><![CDATA[Heart Rhythms]]></category>
		<category><![CDATA[Interventional Cardiology & Surgery]]></category>
		<category><![CDATA[Policy & Ethics]]></category>
		<category><![CDATA[atrial fibrillation]]></category>
		<category><![CDATA[Boston Scientific]]></category>
		<category><![CDATA[food and drug administration]]></category>
		<category><![CDATA[Heart Rhythm Society]]></category>
		<category><![CDATA[warfarin]]></category>
		<category><![CDATA[Watchman]]></category>

		<guid isPermaLink="false">http://cardiobrief.org/?p=14164</guid>
		<description><![CDATA[Encouraging long-term results from the PROTECT AF trial comparing the Watchman left atrial appendage closure device to warfarin in atrial fibrillation patients were presented yesterday at the Heart Rhythm Society meeting in Denver. Previously, the main results of the trial, published in the Lancet, demonstrated that the Watchman was noninferior to warfarin, but the total number of events in the trial was small. In addition, there were more safety problems, as might be expected, in the early days after implantation. The FDA required the company to perform a confirmatory trial. That trial, PREVAIL, has been the subject of considerable controversy. Now, <a class="entry-excerpt-link" href="http://cardiobrief.org/2013/05/10/encouraging-4-year-results-for-watchman-device-in-af-patients/">More&#8230;</a><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=cardiobrief.org&#038;blog=6145391&#038;post=14164&#038;subd=cardiobrief&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://cardiobrief.org/2013/05/10/encouraging-4-year-results-for-watchman-device-in-af-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://2.gravatar.com/avatar/5942cc097b5e0e6b0bc9d26e5c4fb3a1?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">Larry</media:title>
		</media:content>

		<media:content url="http://b-i.forbesimg.com/larryhusten/files/2013/05/Watchman_2-300x298.jpg" medium="image" />
	</item>
		<item>
		<title>Bruise Control: Continued Warfarin Beats Heparin Bridging During Device Implantation</title>
		<link>http://cardiobrief.org/2013/05/09/bruise-control-continued-warfarin-beats-heparin-bridging-during-device-implantation/</link>
		<comments>http://cardiobrief.org/2013/05/09/bruise-control-continued-warfarin-beats-heparin-bridging-during-device-implantation/#comments</comments>
		<pubDate>Thu, 09 May 2013 18:57:29 +0000</pubDate>
		<dc:creator>Larry Husten</dc:creator>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[Anticoagulant]]></category>
		<category><![CDATA[heparin]]></category>
		<category><![CDATA[ICDs]]></category>
		<category><![CDATA[pacemakers]]></category>
		<category><![CDATA[warfarin]]></category>

		<guid isPermaLink="false">http://cardiobrief.org/?p=14162</guid>
		<description><![CDATA[Many patients receiving an ICD or a pacemaker are already receiving oral anticoagulants. Current guidelines recommend replacement of the oral anticoagulant with the temporary use of heparin as a bridging strategy. Now a new study, BRUISE CONTROL (Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial), offers convincing evidence that this strategy is not beneficial and, in fact, results in an increase in device-pocket hematoma. Results of the trial were presented today at the Heart Rhythm Society meeting in Denver and published simultaneously in the New England Journal of Medicine. A group of mostly Canadian investigators <a class="entry-excerpt-link" href="http://cardiobrief.org/2013/05/09/bruise-control-continued-warfarin-beats-heparin-bridging-during-device-implantation/">More&#8230;</a><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=cardiobrief.org&#038;blog=6145391&#038;post=14162&#038;subd=cardiobrief&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://cardiobrief.org/2013/05/09/bruise-control-continued-warfarin-beats-heparin-bridging-during-device-implantation/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
	
		<media:content url="http://2.gravatar.com/avatar/5942cc097b5e0e6b0bc9d26e5c4fb3a1?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">Larry</media:title>
		</media:content>
	</item>
		<item>
		<title>Another Disappointing Study For Fish Oil Supplements</title>
		<link>http://cardiobrief.org/2013/05/08/another-disappointing-study-for-fish-oil-supplements/</link>
		<comments>http://cardiobrief.org/2013/05/08/another-disappointing-study-for-fish-oil-supplements/#comments</comments>
		<pubDate>Wed, 08 May 2013 21:04:18 +0000</pubDate>
		<dc:creator>Larry Husten</dc:creator>
				<category><![CDATA[Heart Failure]]></category>
		<category><![CDATA[Heart Rhythms]]></category>
		<category><![CDATA[Prevention, Epidemiology & Outcomes]]></category>
		<category><![CDATA[Alpha-Linolenic acid]]></category>
		<category><![CDATA[Atherosclerosis]]></category>
		<category><![CDATA[Cardiovascular disease]]></category>
		<category><![CDATA[Docosahexaenoic acid]]></category>
		<category><![CDATA[Fatty acid]]></category>
		<category><![CDATA[Fish oil]]></category>
		<category><![CDATA[Omega-3 fatty acid]]></category>

		<guid isPermaLink="false">http://cardiobrief.org/?p=14159</guid>
		<description><![CDATA[Another large study has failed to find any benefits  for  fish oil supplements. The Italian Risk and Prevention Study, published in the New England Journal of Medicine, enrolled 12,513 people who had not had a myocardial infarction but had evidence of atherosclerosis or had multiple cardiovascular risk factors. The patients were randomized to either a fish oil supplement (1 gram daily of n-3 fatty acids) or placebo. After 5 years of followup, the primary endpoint&#8211; the time to death from cardiovascular causes or admission to the hospital for cardiovascular causes&#8211; had occurred in 11.7% of the fish oil <a class="entry-excerpt-link" href="http://cardiobrief.org/2013/05/08/another-disappointing-study-for-fish-oil-supplements/">More&#8230;</a><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=cardiobrief.org&#038;blog=6145391&#038;post=14159&#038;subd=cardiobrief&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://cardiobrief.org/2013/05/08/another-disappointing-study-for-fish-oil-supplements/feed/</wfw:commentRss>
		<slash:comments>3</slash:comments>
	
		<media:content url="http://2.gravatar.com/avatar/5942cc097b5e0e6b0bc9d26e5c4fb3a1?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">Larry</media:title>
		</media:content>

		<media:content url="http://b-i.forbesimg.com/larryhusten/files/2013/05/300px-Fish_oil_softgel_2.jpg" medium="image">
			<media:title type="html">A typical softgel</media:title>
		</media:content>
	</item>
		<item>
		<title>Longer Detection Time Helps Prevent Unnecessary ICD Shocks</title>
		<link>http://cardiobrief.org/2013/05/07/longer-detection-time-helps-prevent-unnecessary-icd-shocks/</link>
		<comments>http://cardiobrief.org/2013/05/07/longer-detection-time-helps-prevent-unnecessary-icd-shocks/#comments</comments>
		<pubDate>Tue, 07 May 2013 20:54:31 +0000</pubDate>
		<dc:creator>Larry Husten</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://cardiobrief.org/?p=14156</guid>
		<description><![CDATA[Increasing the detection intervals in ICD programming can reduce the number of unnecessary or inappropriate shocks, according to results of the ADVANCE III study published in JAMA. A group of Italian investigators randomized 1,902 patients receiving an ICD to programming with either long- or standard-detection intervals. After 12 months of followup, patients in the long-detection group had a significant reduction in the primary endpoint, which was the total number of antitachycardia pacing episodes and shocks: &#8230; Click here to read the full story on Forbes. &#160;<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=cardiobrief.org&#038;blog=6145391&#038;post=14156&#038;subd=cardiobrief&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://cardiobrief.org/2013/05/07/longer-detection-time-helps-prevent-unnecessary-icd-shocks/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://2.gravatar.com/avatar/5942cc097b5e0e6b0bc9d26e5c4fb3a1?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">Larry</media:title>
		</media:content>
	</item>
		<item>
		<title>Burton Sobel, Towering Cardiologist, Dead At 75</title>
		<link>http://cardiobrief.org/2013/05/07/burton-sobel-towering-cardiologist-dead-at-75/</link>
		<comments>http://cardiobrief.org/2013/05/07/burton-sobel-towering-cardiologist-dead-at-75/#comments</comments>
		<pubDate>Tue, 07 May 2013 14:19:27 +0000</pubDate>
		<dc:creator>Larry Husten</dc:creator>
				<category><![CDATA[People, Places & Events]]></category>
		<category><![CDATA[Allan Jaffe]]></category>
		<category><![CDATA[Circulation]]></category>
		<category><![CDATA[eugene braunwald]]></category>
		<category><![CDATA[Sobel]]></category>
		<category><![CDATA[TPA]]></category>
		<category><![CDATA[Washington University]]></category>

		<guid isPermaLink="false">http://cardiobrief.org/?p=14153</guid>
		<description><![CDATA[Burton Sobel, a towering scientist and cardiologist, died at home on May 3 at the age of 75. Sobel had been treated in the past for prostate cancer and had suffered a recurrence, but it is not known if this was the immediate cause of his death. Sobel was among the most powerful and influential cardiologists in the 1980s when he played a key early role in the development of fibrinolysis and the first major biotechnology product, TPA. From his perch as the chief of cardiology at Washington University in Saint Louis and as the <a class="entry-excerpt-link" href="http://cardiobrief.org/2013/05/07/burton-sobel-towering-cardiologist-dead-at-75/">More&#8230;</a><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=cardiobrief.org&#038;blog=6145391&#038;post=14153&#038;subd=cardiobrief&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://cardiobrief.org/2013/05/07/burton-sobel-towering-cardiologist-dead-at-75/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://2.gravatar.com/avatar/5942cc097b5e0e6b0bc9d26e5c4fb3a1?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">Larry</media:title>
		</media:content>

		<media:content url="http://b-i.forbesimg.com/larryhusten/files/2013/05/Sobel.jpg" medium="image" />
	</item>
		<item>
		<title>Metaanalysis Finds Same Day Discharge For Low Risk PCI May Be Feasible</title>
		<link>http://cardiobrief.org/2013/05/06/metaanalysis-finds-same-day-discharge-for-low-risk-pci-may-be-feasible/</link>
		<comments>http://cardiobrief.org/2013/05/06/metaanalysis-finds-same-day-discharge-for-low-risk-pci-may-be-feasible/#comments</comments>
		<pubDate>Mon, 06 May 2013 18:34:41 +0000</pubDate>
		<dc:creator>Larry Husten</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://cardiobrief.org/?p=14150</guid>
		<description><![CDATA[Although elective PCI for most low risk patients is extremely safe, overnight observation is still standard practice in the US, largely due to the lack of evidence demonstrating that same-day discharge is safe. Now a new metaanalysis, published online in the Journal of the American College of Cardiology, provides support for same-day discharge in carefully selected low-risk patients. &#8230; Click here to read the full post on Forbes. &#160; &#160; &#160; &#160; &#160; &#160; &#160;<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=cardiobrief.org&#038;blog=6145391&#038;post=14150&#038;subd=cardiobrief&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://cardiobrief.org/2013/05/06/metaanalysis-finds-same-day-discharge-for-low-risk-pci-may-be-feasible/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://2.gravatar.com/avatar/5942cc097b5e0e6b0bc9d26e5c4fb3a1?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">Larry</media:title>
		</media:content>

		<media:content url="http://b-i.forbesimg.com/larryhusten/files/2013/05/300x19830.jpg" medium="image">
			<media:title type="html">LONDON, ENGLAND - OCTOBER 13:  Two NHS staff w...</media:title>
		</media:content>
	</item>
		<item>
		<title>FDA Approves Combination Of Ezetimibe And Atorvastatin</title>
		<link>http://cardiobrief.org/2013/05/03/fda-approves-combination-of-ezetimibe-and-atorvastatin/</link>
		<comments>http://cardiobrief.org/2013/05/03/fda-approves-combination-of-ezetimibe-and-atorvastatin/#comments</comments>
		<pubDate>Fri, 03 May 2013 19:57:58 +0000</pubDate>
		<dc:creator>Larry Husten</dc:creator>
				<category><![CDATA[People, Places & Events]]></category>
		<category><![CDATA[Policy & Ethics]]></category>
		<category><![CDATA[Prevention, Epidemiology & Outcomes]]></category>
		<category><![CDATA[atorvastatin]]></category>
		<category><![CDATA[ezetimibe]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[food and drug administration]]></category>
		<category><![CDATA[Low-density lipoprotein]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[Merck & Co]]></category>
		<category><![CDATA[statins]]></category>
		<category><![CDATA[vytorin]]></category>

		<guid isPermaLink="false">http://cardiobrief.org/?p=14148</guid>
		<description><![CDATA[The FDA has approved a new combination drug from Merck for lowering cholesterol. The drug, which will carry the brand name of Liptruzet, is a combination of two previously approved cholesterol-lowering drugs, ezetimibe and atorvastatin. Merck said the new drug (pronounced &#8220;LIP-true-zett&#8221;) would be commercially available starting next week. Liptruzet will be available as a once-daily tablet combining 10 mg of ezetimibe with either 10, 20, 40, or 80 mg of atorvastatin. In clinical trials Liptruzet lowered LDL cholesterol from 53% to 61%, depending on dosage. &#8230; Click here to read the full post on <a class="entry-excerpt-link" href="http://cardiobrief.org/2013/05/03/fda-approves-combination-of-ezetimibe-and-atorvastatin/">More&#8230;</a><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=cardiobrief.org&#038;blog=6145391&#038;post=14148&#038;subd=cardiobrief&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://cardiobrief.org/2013/05/03/fda-approves-combination-of-ezetimibe-and-atorvastatin/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://2.gravatar.com/avatar/5942cc097b5e0e6b0bc9d26e5c4fb3a1?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">Larry</media:title>
		</media:content>

		<media:content url="http://b-i.forbesimg.com/larryhusten/files/2013/05/Liptruzet-300x155.jpg" medium="image" />
	</item>
		<item>
		<title>Scrutiny Of Sodium Meta-Analysis In Heart Uncovers Duplicated And Missing Data</title>
		<link>http://cardiobrief.org/2013/05/03/scrutiny-of-sodium-meta-analysis-in-heart-uncovers-duplicated-and-missing-data/</link>
		<comments>http://cardiobrief.org/2013/05/03/scrutiny-of-sodium-meta-analysis-in-heart-uncovers-duplicated-and-missing-data/#comments</comments>
		<pubDate>Fri, 03 May 2013 14:22:36 +0000</pubDate>
		<dc:creator>Larry Husten</dc:creator>
				<category><![CDATA[People, Places & Events]]></category>
		<category><![CDATA[Policy & Ethics]]></category>
		<category><![CDATA[Adam Marcus]]></category>
		<category><![CDATA[Retraction Watch]]></category>
		<category><![CDATA[retractions]]></category>
		<category><![CDATA[scientific misconduct]]></category>

		<guid isPermaLink="false">http://cardiobrief.org/?p=14146</guid>
		<description><![CDATA[A meta-analysis published in the journal Heart has been retracted. As Adam Marcus writes in Retraction Watch, the retraction occurred when the journal editors learned &#8220;that two of the six studies included in the review contained duplicated data.  Those studies, it so happens, were conducted by one of the co-authors [of the meta-analysis].&#8221; The article, “Low sodium versus normal sodium diets in systolic heart failure: systematic review and meta-analysis,” was published online in August 2012. In their attempt to investigate the duplicate data, the Heart editors reported &#8220;that the raw data are no longer available <a class="entry-excerpt-link" href="http://cardiobrief.org/2013/05/03/scrutiny-of-sodium-meta-analysis-in-heart-uncovers-duplicated-and-missing-data/">More&#8230;</a><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=cardiobrief.org&#038;blog=6145391&#038;post=14146&#038;subd=cardiobrief&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://cardiobrief.org/2013/05/03/scrutiny-of-sodium-meta-analysis-in-heart-uncovers-duplicated-and-missing-data/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://2.gravatar.com/avatar/5942cc097b5e0e6b0bc9d26e5c4fb3a1?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">Larry</media:title>
		</media:content>

		<media:content url="http://retractionwatch.files.wordpress.com/2013/05/heart-cover-may13.gif?w=700" medium="image">
			<media:title type="html">heart cover may13</media:title>
		</media:content>
	</item>
		<item>
		<title>Japanese Research Scandal Expands To A Second Trial And A Novartis Employee</title>
		<link>http://cardiobrief.org/2013/05/02/japanese-research-scandal-expands-to-a-second-trial-and-a-novartis-employee/</link>
		<comments>http://cardiobrief.org/2013/05/02/japanese-research-scandal-expands-to-a-second-trial-and-a-novartis-employee/#comments</comments>
		<pubDate>Thu, 02 May 2013 21:26:22 +0000</pubDate>
		<dc:creator>Larry Husten</dc:creator>
				<category><![CDATA[People, Places & Events]]></category>
		<category><![CDATA[Policy & Ethics]]></category>
		<category><![CDATA[European Heart Journal]]></category>
		<category><![CDATA[Lancet]]></category>
		<category><![CDATA[Matsubara]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[scientific misconduct]]></category>
		<category><![CDATA[valsartan]]></category>

		<guid isPermaLink="false">http://cardiobrief.org/?p=14142</guid>
		<description><![CDATA[A Japanese research scandal, which has so far centered on actions taken by the once-prominent cardiologist Hiroaki Matsubara, has now expanded. As has been previously reported, several papers authored by Matsubara have been retracted, including, most notably, the main publication of the Kyoto Heart Study in the European Heart Journal. Now, however, questions have been raised about  another clinical trial, the Jikei Heart Trial, which was published in the Lancet in 2007.  (Matsubara was not involved in this trial.) Novartis, which manufactures valsartan (Diovan), the drug studied in both trials, has announced that it is <a class="entry-excerpt-link" href="http://cardiobrief.org/2013/05/02/japanese-research-scandal-expands-to-a-second-trial-and-a-novartis-employee/">More&#8230;</a><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=cardiobrief.org&#038;blog=6145391&#038;post=14142&#038;subd=cardiobrief&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://cardiobrief.org/2013/05/02/japanese-research-scandal-expands-to-a-second-trial-and-a-novartis-employee/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://2.gravatar.com/avatar/5942cc097b5e0e6b0bc9d26e5c4fb3a1?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">Larry</media:title>
		</media:content>
	</item>
		<item>
		<title>Danish Study Finds No Increased CV Risk With Azithromycin In General Population</title>
		<link>http://cardiobrief.org/2013/05/01/danish-study-finds-no-increased-cv-risk-with-azithromycin-in-general-population/</link>
		<comments>http://cardiobrief.org/2013/05/01/danish-study-finds-no-increased-cv-risk-with-azithromycin-in-general-population/#comments</comments>
		<pubDate>Wed, 01 May 2013 21:00:43 +0000</pubDate>
		<dc:creator>Larry Husten</dc:creator>
				<category><![CDATA[People, Places & Events]]></category>
		<category><![CDATA[Policy & Ethics]]></category>
		<category><![CDATA[Prevention, Epidemiology & Outcomes]]></category>
		<category><![CDATA[antibiotics]]></category>
		<category><![CDATA[azithromycin]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Zithromax]]></category>

		<guid isPermaLink="false">http://cardiobrief.org/?p=14138</guid>
		<description><![CDATA[A large observational study found no increased risk for cardiovascular events associated with azithromycin (Zithromax, Pfizer) in a general population of young and middle-age adults. In a paper published  in the New England Journal of Medicine, Danish investigators report the results of a large national observational study comparing people who took azithromycin with matched controls who took no antibiotics and with matched controls who took penicillin V for similar indications. Although there was a significant increase in the risk of death from cardiovascular causes in people taking azithromycin compared with people taking no antibiotics (RR <a class="entry-excerpt-link" href="http://cardiobrief.org/2013/05/01/danish-study-finds-no-increased-cv-risk-with-azithromycin-in-general-population/">More&#8230;</a><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=cardiobrief.org&#038;blog=6145391&#038;post=14138&#038;subd=cardiobrief&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://cardiobrief.org/2013/05/01/danish-study-finds-no-increased-cv-risk-with-azithromycin-in-general-population/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://2.gravatar.com/avatar/5942cc097b5e0e6b0bc9d26e5c4fb3a1?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">Larry</media:title>
		</media:content>

		<media:content url="http://b-i.forbesimg.com/larryhusten/files/2013/05/Zithromax.jpg" medium="image" />
	</item>
		<item>
		<title>FDA Warns That Tolvaptan Can Lead To Serious Liver Injury</title>
		<link>http://cardiobrief.org/2013/05/01/fda-warns-that-tolvaptan-can-lead-to-serious-liver-injury/</link>
		<comments>http://cardiobrief.org/2013/05/01/fda-warns-that-tolvaptan-can-lead-to-serious-liver-injury/#comments</comments>
		<pubDate>Wed, 01 May 2013 17:51:59 +0000</pubDate>
		<dc:creator>Larry Husten</dc:creator>
				<category><![CDATA[Heart Failure]]></category>
		<category><![CDATA[People, Places & Events]]></category>
		<category><![CDATA[Policy & Ethics]]></category>
		<category><![CDATA[food and drug administration]]></category>
		<category><![CDATA[heart failure]]></category>
		<category><![CDATA[liver]]></category>

		<guid isPermaLink="false">http://cardiobrief.org/?p=14135</guid>
		<description><![CDATA[The FDA has issued a drug safety communication concerning tolvaptan (Samsca, Otsuka), a selective vasopression V2-receptor antagonist used in heart failure patients to treat clinically significant hypervolemic and euvolemic hyponatremia. The FDA said tolvaptan &#8220;should not be used for longer than 30 days and should not be used in patients with underlying liver disease because it can cause liver injury, potentially leading to liver transplant or death. &#8220; The liver injury risk was discovered in clinical trials testing tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD). The drug label has been updated and <a class="entry-excerpt-link" href="http://cardiobrief.org/2013/05/01/fda-warns-that-tolvaptan-can-lead-to-serious-liver-injury/">More&#8230;</a><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=cardiobrief.org&#038;blog=6145391&#038;post=14135&#038;subd=cardiobrief&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://cardiobrief.org/2013/05/01/fda-warns-that-tolvaptan-can-lead-to-serious-liver-injury/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://2.gravatar.com/avatar/5942cc097b5e0e6b0bc9d26e5c4fb3a1?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">Larry</media:title>
		</media:content>
	</item>
		<item>
		<title>WSJ Article Fails To Raise Key Questions About Cardiovascular Risk In Children</title>
		<link>http://cardiobrief.org/2013/04/30/wsj-article-fails-to-raise-key-questions-about-cardiovascular-risk-in-children/</link>
		<comments>http://cardiobrief.org/2013/04/30/wsj-article-fails-to-raise-key-questions-about-cardiovascular-risk-in-children/#comments</comments>
		<pubDate>Tue, 30 Apr 2013 19:42:41 +0000</pubDate>
		<dc:creator>Larry Husten</dc:creator>
				<category><![CDATA[Policy & Ethics]]></category>
		<category><![CDATA[Prevention, Epidemiology & Outcomes]]></category>
		<category><![CDATA[HDL]]></category>
		<category><![CDATA[High-density lipoprotein]]></category>
		<category><![CDATA[LDL]]></category>
		<category><![CDATA[obesity]]></category>
		<category><![CDATA[pediatrics]]></category>
		<category><![CDATA[Triglyceride]]></category>
		<category><![CDATA[Wall Street Journal]]></category>

		<guid isPermaLink="false">http://cardiobrief.org/?p=14131</guid>
		<description><![CDATA[There&#8217;s probably no greater public health issue than the long-term  consequences of the childhood obesity epidemic. So the Wall Street Journal should be commended for digging into some of the important science behind this problem in a feature article in today&#8217;s paper. The author, Ron Winslow, is widely regarded as the best working journalist who regularly covers cardiovascular medicine. But I&#8217;m afraid the article fails to raise several key questions about the topic and therefore misses an opportunity to educate people about its complexities. The article deals with the &#8220;growing concerns about the cardiovascular health <a class="entry-excerpt-link" href="http://cardiobrief.org/2013/04/30/wsj-article-fails-to-raise-key-questions-about-cardiovascular-risk-in-children/">More&#8230;</a><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=cardiobrief.org&#038;blog=6145391&#038;post=14131&#038;subd=cardiobrief&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://cardiobrief.org/2013/04/30/wsj-article-fails-to-raise-key-questions-about-cardiovascular-risk-in-children/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://2.gravatar.com/avatar/5942cc097b5e0e6b0bc9d26e5c4fb3a1?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">Larry</media:title>
		</media:content>

		<media:content url="http://b-i.forbesimg.com/larryhusten/files/2013/04/5500725788_b811e380a8_m7.jpg" medium="image">
			<media:title type="html">scale_zero</media:title>
		</media:content>
	</item>
		<item>
		<title>Anticoagulation Update: New Agent For Urgent Anticoagulation Reversal, Pradaxa Label Revised</title>
		<link>http://cardiobrief.org/2013/04/30/anticoagulation-update-new-agent-for-urgent-anticoagulation-reversal-pradaxa-label-revised/</link>
		<comments>http://cardiobrief.org/2013/04/30/anticoagulation-update-new-agent-for-urgent-anticoagulation-reversal-pradaxa-label-revised/#comments</comments>
		<pubDate>Tue, 30 Apr 2013 15:27:32 +0000</pubDate>
		<dc:creator>Larry Husten</dc:creator>
				<category><![CDATA[People, Places & Events]]></category>
		<category><![CDATA[Policy & Ethics]]></category>
		<category><![CDATA[Prevention, Epidemiology & Outcomes]]></category>
		<category><![CDATA[Anticoagulant]]></category>
		<category><![CDATA[boehringer ingelheim]]></category>
		<category><![CDATA[CSL Behring]]></category>
		<category><![CDATA[dabigatran]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[food and drug administration]]></category>
		<category><![CDATA[Kcentra]]></category>
		<category><![CDATA[Prothrombin Complex Concentrate]]></category>

		<guid isPermaLink="false">http://cardiobrief.org/?p=14120</guid>
		<description><![CDATA[Here are two small but important changes in the anticoagulation field: FDA approves new product for urgent reversal of anticoagulation.  &#8230; Pradaxa label gains boxed warning. &#8230; &#160; Click here to read the full story on Forbes. &#160; &#160;<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=cardiobrief.org&#038;blog=6145391&#038;post=14120&#038;subd=cardiobrief&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://cardiobrief.org/2013/04/30/anticoagulation-update-new-agent-for-urgent-anticoagulation-reversal-pradaxa-label-revised/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
	
		<media:content url="http://2.gravatar.com/avatar/5942cc097b5e0e6b0bc9d26e5c4fb3a1?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">Larry</media:title>
		</media:content>

		<media:content url="http://upload.wikimedia.org/wikipedia/commons/thumb/7/7d/Food_and_Drug_Administration_logo.svg/300px-Food_and_Drug_Administration_logo.svg.png" medium="image">
			<media:title type="html">English: Logo of the .</media:title>
		</media:content>
	</item>
		<item>
		<title>Unconventional Analysis Finds Threshold For LDL Reduction With Statins</title>
		<link>http://cardiobrief.org/2013/04/29/unconventional-analysis-finds-threshold-for-ldl-reduction-with-statins/</link>
		<comments>http://cardiobrief.org/2013/04/29/unconventional-analysis-finds-threshold-for-ldl-reduction-with-statins/#comments</comments>
		<pubDate>Mon, 29 Apr 2013 20:09:35 +0000</pubDate>
		<dc:creator>Larry Husten</dc:creator>
				<category><![CDATA[Policy & Ethics]]></category>
		<category><![CDATA[Prevention, Epidemiology & Outcomes]]></category>
		<category><![CDATA[cholesterol]]></category>
		<category><![CDATA[health]]></category>
		<category><![CDATA[hypercholesterolemia]]></category>
		<category><![CDATA[Low-density lipoprotein]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Statin]]></category>

		<guid isPermaLink="false">http://cardiobrief.org/?p=14117</guid>
		<description><![CDATA[Using an unconventional mathematical approach, a group of Japanese researchers say there may be no good reason to reduce LDL cholesterol more than 40 mg/dl. Their research letter has been published online in JAMA Internal Medicine. According to the authors, members of the ALICE (All-Literature Investigation of Cardiovascular Evidence) Group, most meta-analyses use linear models that assume &#8220;a constantly increasing or decreasing risk as the exposure increases or decreases.&#8221; Linear models, however, can be &#8220;misleading,&#8221; they write, because they assume a specific dose-response relationship. By contrast, their new analysis utilizes &#8220;flexible&#8221; models that can more <a class="entry-excerpt-link" href="http://cardiobrief.org/2013/04/29/unconventional-analysis-finds-threshold-for-ldl-reduction-with-statins/">More&#8230;</a><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=cardiobrief.org&#038;blog=6145391&#038;post=14117&#038;subd=cardiobrief&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://cardiobrief.org/2013/04/29/unconventional-analysis-finds-threshold-for-ldl-reduction-with-statins/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://2.gravatar.com/avatar/5942cc097b5e0e6b0bc9d26e5c4fb3a1?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">Larry</media:title>
		</media:content>
	</item>
		<item>
		<title>Edwards CEO Sold Stock 2 Weeks Before It Tanked</title>
		<link>http://cardiobrief.org/2013/04/26/edwards-ceo-sold-stock-2-weeks-before-it-tanked/</link>
		<comments>http://cardiobrief.org/2013/04/26/edwards-ceo-sold-stock-2-weeks-before-it-tanked/#comments</comments>
		<pubDate>Fri, 26 Apr 2013 04:14:10 +0000</pubDate>
		<dc:creator>Larry Husten</dc:creator>
				<category><![CDATA[Interventional Cardiology & Surgery]]></category>
		<category><![CDATA[People, Places & Events]]></category>
		<category><![CDATA[Policy & Ethics]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[Sapien]]></category>
		<category><![CDATA[TAVR]]></category>

		<guid isPermaLink="false">http://cardiobrief.org/?p=14112</guid>
		<description><![CDATA[(Updated) Earlier this week the stock of Edwards Lifesciences tanked after the company announced weak Sapien sales and lowered its sales guidance for the rest of the year. The stock, which had been trading in the low 80s for the past month, dropped a heartbreaking 22% on Wednesday in response to the news and closed at 65 on Thursday. But Edwards chairman and CEO Michael Mussallem didn&#8217;t suffer along with his shareholders. As reported by GuruFocus, Mussallem sold 35,000 shares of his stock on April 10 at 83.37 per share netting him nearly $3 million. <a class="entry-excerpt-link" href="http://cardiobrief.org/2013/04/26/edwards-ceo-sold-stock-2-weeks-before-it-tanked/">More&#8230;</a><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=cardiobrief.org&#038;blog=6145391&#038;post=14112&#038;subd=cardiobrief&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://cardiobrief.org/2013/04/26/edwards-ceo-sold-stock-2-weeks-before-it-tanked/feed/</wfw:commentRss>
		<slash:comments>2</slash:comments>
	
		<media:content url="http://2.gravatar.com/avatar/5942cc097b5e0e6b0bc9d26e5c4fb3a1?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">Larry</media:title>
		</media:content>

		<media:content url="http://b-i.forbesimg.com/larryhusten/files/2013/04/Mussallem.jpg" medium="image" />
	</item>
		<item>
		<title>Conflicting Results From Two Trials Of Cardiac Resynchronization Therapy</title>
		<link>http://cardiobrief.org/2013/04/25/conflicting-results-from-two-trials-of-cardiac-resynchronization-therapy/</link>
		<comments>http://cardiobrief.org/2013/04/25/conflicting-results-from-two-trials-of-cardiac-resynchronization-therapy/#comments</comments>
		<pubDate>Thu, 25 Apr 2013 22:00:55 +0000</pubDate>
		<dc:creator>Larry Husten</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://cardiobrief.org/?p=14109</guid>
		<description><![CDATA[Two new trials have ended up reporting conflicting results regarding the expansion of the indication for cardiac resynchronization therapy (CRT) for patients without a wide QRS interval.  The positive results of the smaller trial seem likely to be undermined by the early stopping of the much larger trial. The first trial, NARROW-CRT, published in Circulation: Arrhythmia and Electrophysiology, concluded that CRT &#8220;improved clinical status in some patients with ischemic cardiomyopathy, mild-to-moderate symptoms, narrow QRS duration, and mechanical dyssynchrony on echocardiography.&#8221; The second trial, EchoCRT, which was testing CRT in heart failure patients with narrow QRS, <a class="entry-excerpt-link" href="http://cardiobrief.org/2013/04/25/conflicting-results-from-two-trials-of-cardiac-resynchronization-therapy/">More&#8230;</a><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=cardiobrief.org&#038;blog=6145391&#038;post=14109&#038;subd=cardiobrief&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://cardiobrief.org/2013/04/25/conflicting-results-from-two-trials-of-cardiac-resynchronization-therapy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://2.gravatar.com/avatar/5942cc097b5e0e6b0bc9d26e5c4fb3a1?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">Larry</media:title>
		</media:content>

		<media:content url="http://b-i.forbesimg.com/larryhusten/files/2013/04/6549497793_ab696cbc17_m4.jpg" medium="image">
			<media:title type="html">Stop Sign with Divided Highway</media:title>
		</media:content>
	</item>
		<item>
		<title>Another Cleveland Clinic Study Links TMAO To Atherosclerosis</title>
		<link>http://cardiobrief.org/2013/04/24/another-cleveland-clinic-study-links-tmao-to-atherosclerosis/</link>
		<comments>http://cardiobrief.org/2013/04/24/another-cleveland-clinic-study-links-tmao-to-atherosclerosis/#comments</comments>
		<pubDate>Wed, 24 Apr 2013 21:15:32 +0000</pubDate>
		<dc:creator>Larry Husten</dc:creator>
				<category><![CDATA[People, Places & Events]]></category>
		<category><![CDATA[Prevention, Epidemiology & Outcomes]]></category>
		<category><![CDATA[Cardiovascular disease]]></category>
		<category><![CDATA[Cleveland Clinic]]></category>
		<category><![CDATA[Heart disease]]></category>
		<category><![CDATA[Nature Medicine]]></category>
		<category><![CDATA[TMAO]]></category>
		<category><![CDATA[Trimethylamine N-oxide]]></category>

		<guid isPermaLink="false">http://cardiobrief.org/?p=14107</guid>
		<description><![CDATA[A new study from the Cleveland Clinic research group headed by Stanley Hazen offers more evidence in support of the hypothesis that TMAO (trimethylamine-N-oxide) may play a role in the development of heart disease. The new research, published in the New England Journal of Medicine, follows closely on a related study published recently in Nature Medicine that received broad public attention. The Nature Medicine paper demonstrated that digestive tract bacteria metabolize carnitine into trimethylamine-N-oxide (TMAO), which had previously been linked to atherosclerosis in animals. The new research in NEJM focuses on another pathway that leads to <a class="entry-excerpt-link" href="http://cardiobrief.org/2013/04/24/another-cleveland-clinic-study-links-tmao-to-atherosclerosis/">More&#8230;</a><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=cardiobrief.org&#038;blog=6145391&#038;post=14107&#038;subd=cardiobrief&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://cardiobrief.org/2013/04/24/another-cleveland-clinic-study-links-tmao-to-atherosclerosis/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://2.gravatar.com/avatar/5942cc097b5e0e6b0bc9d26e5c4fb3a1?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">Larry</media:title>
		</media:content>

		<media:content url="http://b-i.forbesimg.com/larryhusten/files/2013/04/Hazen.jpeg" medium="image" />
	</item>
		<item>
		<title>BLOCK HF: CRT Superior To Conventional Pacing In Heart Failure Patients With AV Block</title>
		<link>http://cardiobrief.org/2013/04/24/block-hf-crt-superior-to-conventional-pacing-in-heart-failure-patients-with-av-block/</link>
		<comments>http://cardiobrief.org/2013/04/24/block-hf-crt-superior-to-conventional-pacing-in-heart-failure-patients-with-av-block/#comments</comments>
		<pubDate>Wed, 24 Apr 2013 21:04:30 +0000</pubDate>
		<dc:creator>Larry Husten</dc:creator>
				<category><![CDATA[Heart Failure]]></category>
		<category><![CDATA[Heart Rhythms]]></category>
		<category><![CDATA[Anne Curtis]]></category>
		<category><![CDATA[Atrioventricular Block]]></category>
		<category><![CDATA[Ejection fraction]]></category>
		<category><![CDATA[heart failure]]></category>
		<category><![CDATA[Medtronic]]></category>
		<category><![CDATA[new england journal of medicine]]></category>
		<category><![CDATA[QRS complex]]></category>

		<guid isPermaLink="false">http://cardiobrief.org/?p=14104</guid>
		<description><![CDATA[&#160; Patients with atrioventricular (AV) block generally receive right ventricular pacing; cardiac resynchronization therapy (CRT) has been restricted to patients with a low ejection fraction and a wide QRS duration. However, RV pacing may worsen LV dysfunction in AV block patients with low ejection fractions. Previous studies have raised the possibility that these patients may benefit from biventricular pacing with a CRT device. Now, results from the Medtronic-sponsored BLOCK HF (Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block) trial, published in the New England Journal of Medicine, lend more support for <a class="entry-excerpt-link" href="http://cardiobrief.org/2013/04/24/block-hf-crt-superior-to-conventional-pacing-in-heart-failure-patients-with-av-block/">More&#8230;</a><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=cardiobrief.org&#038;blog=6145391&#038;post=14104&#038;subd=cardiobrief&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://cardiobrief.org/2013/04/24/block-hf-crt-superior-to-conventional-pacing-in-heart-failure-patients-with-av-block/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://2.gravatar.com/avatar/5942cc097b5e0e6b0bc9d26e5c4fb3a1?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">Larry</media:title>
		</media:content>

		<media:content url="http://b-i.forbesimg.com/larryhusten/files/2013/04/Anne-Curtis-Headshot-e1366824896719-279x300.jpg" medium="image" />
	</item>
		<item>
		<title>Study Suggests Benefit For Beta Blockers During Noncardiac Surgery</title>
		<link>http://cardiobrief.org/2013/04/23/study-suggests-benefit-for-beta-blockers-during-noncardiac-surgery/</link>
		<comments>http://cardiobrief.org/2013/04/23/study-suggests-benefit-for-beta-blockers-during-noncardiac-surgery/#comments</comments>
		<pubDate>Tue, 23 Apr 2013 20:10:03 +0000</pubDate>
		<dc:creator>Larry Husten</dc:creator>
				<category><![CDATA[Interventional Cardiology & Surgery]]></category>
		<category><![CDATA[Prevention, Epidemiology & Outcomes]]></category>
		<category><![CDATA[beta blockers]]></category>
		<category><![CDATA[JAMA]]></category>
		<category><![CDATA[Observational study]]></category>
		<category><![CDATA[surgery]]></category>

		<guid isPermaLink="false">http://cardiobrief.org/?p=14102</guid>
		<description><![CDATA[The use of perioperative beta-blockade for noncardiac surgery has been declining as a result of the controversial POISE study, which turned up evidence for harm associated with extended-release metoprolol in this setting. Now a large new observational study published in JAMA offers a contrary perspective by suggesting that perioperative beta-blockade may be beneficial in low- to intermediate-risk patients. But without better evidence the debate about this topic is unlikely to be resolved. Martin London and colleagues performed a retrospective analysis of 136,745 patients who underwent noncardiac surgery at VA hospitals, 40% of whom received beta-blockade. <a class="entry-excerpt-link" href="http://cardiobrief.org/2013/04/23/study-suggests-benefit-for-beta-blockers-during-noncardiac-surgery/">More&#8230;</a><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=cardiobrief.org&#038;blog=6145391&#038;post=14102&#038;subd=cardiobrief&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://cardiobrief.org/2013/04/23/study-suggests-benefit-for-beta-blockers-during-noncardiac-surgery/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://2.gravatar.com/avatar/5942cc097b5e0e6b0bc9d26e5c4fb3a1?s=96&#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">Larry</media:title>
		</media:content>
	</item>
	</channel>
</rss>
